Clinical trials: Geriatric Cancer Patients
Cognitive Impairment
Health Care Courses of Elderly Hospitalized Patients for Inappropriate Reasons: Qualitative and Economic Analyzes
For almost 17 % of cases patients over 75 years are sent for inappropriate reasons to the emergency unit. They are described as inappropriate hospitalization because they don't require the use of technical platform or diagnostic…
- Trial name
- PAGE (NCT02749669)
- Testing
- Qualitative research
- Where
- France
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Régis AUBRY
Breast Cancer
Study on the Efficacy and Safety of "Body-Tuning, Voice-Tuning, Mind-Tuning" Three-Dimensional Integrated Art Therapy in Regulating the Physical-Mental-Social Status of Young and Middle-Aged Breast Cancer Patients After Surgery
To evaluate the improvement effect of the "Body-Tuning, Voice-Tuning, Mind-Tuning" three-dimensional integrated art therapy on insomnia and physical-mental-social status in breast cancer patients aged ≤45 years, and to explore…
- Trial name
- ArtRehab (NCT07815262)
- Testing
- ArtRehab
- Where
- China
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Keda Yu
MCL, Mantle Cell Lymphoma
Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma
This is a phase II trial, with the aim of developing a chemotherapy-free regimen for untreated patients with mantle cell lymphoma (MCL).
- Trial name
- ALTAMIRA (NCT05214183)
- Testing
- Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma
- Where
- 20 sites in Denmark, Finland and 3 more
- Volunteers
- 81 people
- Sponsor
- Nordic Lymphoma Group
Carcinoma, Solid Tumor
The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0)
This is an open-label, single-arm, Phase II investigator-initiated trial of hypofractionated radiotherapy combined with PD-L1 inhibitor sequential GM-CSF and thymopentin for treatment of elderly patients with advanced solid…
- Trial name
- NCT06112041
- Testing
- ADC Combined With Radiotherapy, PD-L1 Sequential GM-CSF and Thymopentin
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Non Small Cell Lung Cancer
Pembrolizumab in Elderly Patients With Advanced Lung Cancer
This is a multi-center phase II trial of intravenous (IV) Pembrolizumab MK-3475 in subjects older than 70 years with advanced Non-small cell Lung Cancer (NSCLC) expressing Programmed death-ligand 1 (PD-L1).
- Trial name
- NCT03293680
- Testing
- Pembrolizumab
- Where
- 12 sites in Spain
- Volunteers
- 83 people
- Sponsor
- Spanish Lung Cancer Group
Acute Myeloid Leukemia
Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML
To determine the feasibility of fludarabine and cytarabine as continuous infusion plus granulocyte-colony stimulating factor priming for elderly patients with resistant acute myeloid leukemia other than acute promyelocytic…
- Trial name
- NCT00529880
- Testing
- Fludarabine , cytarabine
- Where
- South Korea
- Volunteers
- 19 people
- Sponsor
- Cooperative Study Group A for Hematology
CCND1 Positive, CCND2 Positive
Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma
This phase II trial studies how well ibrutinib and rituximab work in treating patients with mantle cell lymphoma that has come back or has not responded to treatment or older patients with newly diagnosed mantle cell lymphoma.
- Conditions
- CCND1 Positive, CCND2 Positive, CCND3 Positive, CD20 Positive
- Trial name
- NCT01880567
- Testing
- Ibrutinib, Laboratory Biomarker Analysis, Rituximab
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- M.D. Anderson Cancer Center
Glioma
Hypofractionated Imrt (Vmat-Ra) For Elderly Patients With Newly Diagnosed High Grade Glioma
To assess the effect of IMRT using VMAT rapidarc approach, followed by adjuvant temozolomide on survival and quality of life in elderly, poor performance status patients with newly diagnosed HGG.
- Trial name
- NCT02099487
- Testing
- Radiation
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Istituto Clinico Humanitas
Geriatric Assessment, Adjuvant Drug Therapy
Aspects of Adjuvant CDK4/6 Inhibitors in Older Breast Cancer Patients - Focusing on Geriatric Screening
Older breast cancer patients should not be categorically excluded from adjuvant therapies, including the recommended CDK4/6 inhibitors (CDK4/6i) administered in combination with endocrine therapy.
- Conditions
- Geriatric Assessment, Adjuvant Drug Therapy, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Trial name
- FUTURE (NCT07273357)
- Where
- 5 sites in Sweden
- Volunteers
- 200 people
- Sponsor
- Region Jönköping County
Non-Small-Cell Lung Carcinoma
Phase II Iressa Versus Vinorelbine (INVITE)
This is a randomized, open label, parallel group, multi-centre, phase II study of progression free survival, comparing oral ZD1839 (IRESSA™) (250 mg tablet once daily) to vinorelbine 30 mg/m2 infusion on days 1 and 8 of a 21-day…
- Trial name
- NCT00256711
- Testing
- Gefitinib, Vinorelbine
- Where
- 55 sites in Australia, Brazil and 8 more
- Volunteers
- 192 people
- Sponsor
- AstraZeneca
Esophageal Squamous Cell Carcinoma
Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Cancer.
This Prospective, single-arm Phase Ⅱ study is to determine the efficacy and safety of Once-daily Simultaneous Modulated Accelerated Radiotherapy combined with S-1/DDP for geratic esophageal squamous cell carcinoma patients.
- Trial name
- NCT02606916
- Testing
- SMART, DDP, S-1
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Sun Yat-sen University
Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer
Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
This phase II trial is studying how well giving imatinib mesylate together with paclitaxel works in treating older patients with stage IIIB or stage IV non-small cell lung cancer.
- Conditions
- Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00408460
- Testing
- imatinib mesylate, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- University of Washington
Mantle Cell Lymphoma
PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma
This is a prospective, multicenter, phase II study, in elderly patients affected by Mantle cell lymphoma (MCL) defined as unfit/frail according to Simplified Geriatric Assessment (sGA) and previously untreated.
- Trial name
- FIL_PUMA (NCT07207785)
- Testing
- Pirtobrutinib
- Where
- 20 sites in Italy
- Volunteers
- 56 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Esophageal Carcinoma
Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age
This study is a Single Arm, Prospective, Exploratory, Single Center Phase II Clinical Study to evaluate the effectiveness of the combination of Serplulimab and Concurrent Chemoradiotherapy in the treatment of elderly patients…
- Trial name
- NCT06354218
- Testing
- Serplulimab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Cancer, Frailty
Association of ICU Admission Time, Age Stratification, and Clinical Frailty Scale With 30-Day Mortality in Geriatric Oncology Patients
Geriatric oncology patients frequently require intensive care admission and are at increased risk of adverse outcomes due to advanced age, frailty, and critical illness.
- Conditions
- Cancer, Frailty, Mortality
- Trial name
- NCT07825090
- Testing
- Observation
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people
- Sponsor
- Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
Lymphoma
Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different ways may kill more cancer cells.
- Trial name
- NCT00053768
- Testing
- filgrastim, EPOCH regimen, cyclophosphamide
- Where
- 175 sites in Germany, Switzerland
- Volunteers
- 392 people
- Sponsor
- German High-Grade Non-Hodgkin's Lymphoma Study Group
Breast Cancer, Recurrent Breast Cancer
A Study of Diffusing Alpha Radiation Therapy for Patients With Breast Carcinoma in Frail or Elderly Patients.
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for the treatment of newly diagnosed or Recurrent Breast Carcinoma in frail or elderly patients.
- Conditions
- Breast Cancer, Recurrent Breast Cancer, Breast Carcinoma
- Trial name
- NCT06202118
- Testing
- Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Alpha Tau Medical LTD.
Prostate Cancer
Pneumatic Compression and Post-induction Hypotension
The purpose of this study is to evaluate the effect of pneumatic compression on post-induction hypotension in elderly patients undergoing robot assisted laparoscopic prostatectomy.
- Trial name
- NCT05343689
- Testing
- Pneumatic compression
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Asan Medical Center
Colorectal Neoplasms
Geriatric Intervention in Frail Elderly Patients With Colorectal Cancer
This is a randomized, controlled trial on frail elderly patients (aged 65+) with colorectal cancer. The patients will be randomized into two groups. The control group will receive standard surgical treatment.
- Trial name
- NCT01321658
- Testing
- Geriatric intervention
- Where
- Norway
- Volunteers
- 122 people
- Sponsor
- Oslo University Hospital
Carcinoma, Non-Small-Cell Lung, ErbB Receptors
Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older
Continuous treatment until progression or occurence of intolerable Adverse Event (AE) or end of trial. The end of trial is one year after the last patient has entered the study.
- Trial name
- NCT02514174
- Testing
- Afatinib
- Where
- 10 sites in United States
- Volunteers
- 25 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.